Mi­cro­cap biotech Vista­Gen turned to pen­ny­s­tock af­ter PhII re­sults show its de­pres­sion drug does­n't work so­lo

Vista­Gen Ther­a­peu­tics’ AV-101 has flunked an ex­plorato­ry Phase II, quash­ing hopes that the drug could work as a monother­a­py for treat­ment-re­sis­tant de­pres­sion.

To be sure …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.